Group items tagged

Join us for a comprehensive look at the latest innovations in surgery which will feature expert speakers exploring new techniques, tools, and technologies transforming the field

The Pharmacists Defence Association (PDA) has expressed its interest to support pharmacists impacted with the latest announcement of the closure of Tesco pharmacies. "Tesco have followed ASDA and LloydsPharmacy (at Sainsbury's) to announce cost cutting changes to their stores, impacting hundreds of jobs," the association said. The PDA's interests in the announcement relate to the planned closure of eight in-store Tesco pharmacies and the impact of those closures upon pharmacists, however the union is of course concerned for all those impacted. The PDA Union will support individual PDA members impacted by the decision so that they are aware of, and can exercise, their rights at work in relation to this situation. Paul Day, PDA Union Director said, "In addition to the immediate impact on pharmacists employed at the stores marked for closure, this is the third instance in just twelve days of reductions in the overall access to a pharmacy for NHS patients. We expect those who represent communities to be concerned about the loss of a key part of their local NHS service."

The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years. Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book. Additionally, children living with someone immunosuppressed will be eligible to get the first dose of the Covid-19 vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI). According to the NHS, there are around 500,000 eligible children in the latest cohort. GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

The NHS is going to roll out a revolutionary 30-minute treatment for advanced womb cancer for women across England. The drug, called Dostarlimab, would benefit around 100 women with advanced and often incurable endometrial cancer every year after the NHS agreed early access to the treatment through the Cancer Drugs Fund. It works by attaching to a specific protein on the surface of the cancer cells, helping the immune system to detect and attack it. The treatment takes just 30 minutes to administer through the blood stream every three weeks over a 12-week period. The move is in line with the NHS Long Term Plan which aims to provide the latest cutting-edge treatments and therapies for patients.

The Pharmacists' Defence Association raised concerns over the practice of firing and rehiring employees, which often leads to denial of individuals' rights to redundancy, forcing them to face cuts to their terms and conditions. It noted that some employers may use the 'fire and rehire' practice to force staff to accept lower wages, different hours, or other changes in working conditions. It cited an example of a lawsuit in which Tesco lost a High Court battle when Usdaw won a case to protect workers from unfair tactics. The PDA said although the trade union won the case, the practice of firing and rehiring can still be legal in some circumstances. However, it believes the practice is both immoral and unethical.

Community pharmacists in England have slammed the government's latest decision to reduce the number of people who get a free winter flu jab in the 2022-23 flu season, as concerns related to Covid-19 still exist. This follows a letter from the NHS England and NHS Improvement (NHSE&I) to clinicians, which stated that the flu vaccination service in 2022-23 will be offered to patient groups eligible in line with pre-pandemic recommendations. The eligibility was widened significantly after the pandemic struck in 2020 to help reduce the death toll from the Covid-19. With the change in place people aged 50-64 and schoolchildren aged 11-15 will not be eligible to receive the free jabs on the NHS next winter, pushing millions of people to pay for their jabs privately. It further recommended that vaccination for frontline healthcare workers and social care workers should be provided by employers as part of the organisation's policy to prevent the transmission of infection.

The national pharmacy bodies has created 'Save Our Pharmacies' campaign website to give new focus to calls for fair pharmacy funding in England. The newly launched site contains key messages for public, politicians and stakeholders, and hosts campaign resources to be used by pharmacy teams. The pharmacy bodies encourage members of the public and pharmacy teams to show their support for the campaign on social media, as well as signing the petition and contacting their local MPs about fair funding. A further resource in the form of a window poster is being printed and will shortly be mailed out to all community pharmacies in England. It is the latest output of a joint programme of work being coordinated by PSNC, CCA, AIM and the NPA.

ENT live webinar 2023 is intended to give the most recent updates on specialty topics that will help general Otorhinolaryngologists to stay updated with the latest evidence and best practice.

The Pharmacists' Defence Association (PDA) is supporting pharmacists in England whose employment has been impacted by the creation of new NHS structures. As a result of the 2022 Health and Care Act, Integrated Care Systems (ICSs) were established in England, and Clinical Commissioning Groups (CCGs) were closed on 1 July 2022. Each of the ICSs includes two key parts: an Integrated Care Board (ICB) and an Integrated Care Partnership (ICP). The association said: "The previous structures in England, established by the Health and Social Care Act 2012, originally had over 200 clinical commissioning groups. This number had reduced over recent years via mergers." "However, this latest shift to just 42 commissioning entities means a significant change to significantly larger geographies and populations covered by each ICS. Although each ICS and its activity can be subdivided into 'places', and within places into 'neighbourhoods', it is at the ICS level that the employer is formed." "Whereas CCGs previously employed many local health professionals, including pharmacists, the new arrangements mean that ICBs are now that employer. The PDA is supporting members who have contacted its Service Centre about the impact of these changes."

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised 'no one should stop taking valproate without advice from their healthcare professional.' The latest data on the use of valproate in England revealed that in the last 6 months the number of pregnant women prescribed valproate in a 6-month period has fallen from 68 women in April to September 2018, to 17 women in October 2021 to March 2022. In light of concerns that the current regulatory requirements for safe use are not being consistently followed, the MHRA conducted a review of the available data and asked for advice from the independent Commission on Human Medicines (CHM). "The CHM has advised that no one under the age of 55 should be initiated on valproate unless two specialists independently consider and document that there is no other effective or tolerated treatment," said MHRA. "Where possible, existing patients should be switched to another treatment unless two specialists independently consider and document that there is no other effective or tolerated treatment or the risks do not apply."

The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the impact that high medicine price rises are having on contractor. Recently, the Department of Health and Social Care (DHSC) has granted the final list of price concessions for December 2022. The latest additions bring the total number of concessionary prices granted for the month of December to 198, surpassing the previous record of 159 granted in September 2022. PSNC has heard from hundreds of community pharmacy contractors who are paying inflated prices for antibiotics used for the treatment of Strep A and who have rightly been concerned about the lack of certainty around the final reimbursement prices for these medicines. It added: "We welcomed the involvement of the Competition and Markets Authority (CMA) to look into the pricing of antibiotics. But the number of reports we are getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis."

The Pharmacists' Defence Association (PDA) has created a form to help locum and other pharmacists to report about breach of NHS contract by community pharmacy. According to the association, they have been told by increasing number of pharmacists about contractors closing pharmacies, despite a locum readily available to cover the shift. The PDA said this is an issue of NHS contractual breach and creates difficulties for patients, and so they have created the form to assist members to report unnecessary closures to the relevant NHS England & Improvement pharmacy contract team. A locum pharmacist, who does not wish to be named, has alleged that a community pharmacy declined their offer to cover an extra shift for £5 more per hour, and decided to close the store, denying the public access to services. The pharmacist recalled the occasion while writing in the PDA's latest member voice article.

The recent industrial action by junior doctors and hospital dental trainees, which is considered the longest strike in NHS history, caused a significant impact on the NHS services. Data published by NHS England showed that 113,779 inpatient and outpatient appointments were rescheduled due to the strike, which began on Wednesday 3 January at 7.00am and finished at 7.00am on Tuesday 9 January. Junior doctors make up around half of all doctors in the health service, but 25,446 staff remained absent from work at the peak of the last week's latest action. The ongoing dispute between junior doctors and government over the 2022/23 pay award has disrupted more than one million hospital appointments so far. The junior doctors' strike in December 2023 impacted 86,329 hospital appointments, and their previous action in October saw over 86,000 appointments cancelled.

In a groundbreaking move towards modernising healthcare, England's National Health Service (NHS) has successfully implemented digital prescriptions, as reported by the World Health Organization (WHO) in its latest regional digital health report. Since January 2024, patients across England have had access to their prescription information through the NHS App, marking a significant leap in healthcare accessibility and efficiency. With over 33 million registered users, representing 75 per cent of the adult population, the NHS App has become a vital tool in managing healthcare online. The introduction of digital prescriptions allows users to order repeat prescriptions online without the need for a GP visit. This innovation has witnessed a surge in digital requests, with over 3.1 million repeat prescriptions processed monthly.

Two Indian pharmaceutical companies, Cipla and Glenmark, are pulling back certain products from the American market due to manufacturing concerns, according to the US Food and Drug Administration (USFDA). A New Jersey-based subsidiary of Cipla is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution due to "short fill", news agency PTI reported, quoting the latest Enforcement Report issued by the US health regulator. Produced at the company's Indore SEZ plant, this medication is used to manage symptoms associated with lung diseases, such as asthma, chronic bronchitis and emphysema. Cipla USA decided to recall the affected lot following complaints of less fill volume in respule and few drops of liquid observed in the intact pouch, the USFDA said, adding that the drug maker initiated the Class II recall in the US market on March 26 this year.

The latest formulation of XGEVA (denosumab) is now available to patients in the UK, offering a more convenient treatment option for bone metastasis. It is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP). Denosumab (XGEVA) is used to prevent serious bone-related complications resulting from bone metastasis in adults and to treat giant cell tumour of bone in both adults and adolescents. The medicine was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. In contrast to the current vial presentation, this simplifies the administration process, reducing the volume of liquid injected and lowering the risk of dosing errors. The product was authorised in 30 days by the MHRA, thanks to the new IRP that facilitated a rapid approval process.

A recent survey conducted by the British Society Attitudes (BSA) and published by the King's Fund and the Nuffield Trust highlighted people's satisfaction with the National Health Services (NHS) to be a new record low since the survey's inception in 1983. The latest findings that are based on the public satisfaction and opinion with the NHS and social care, and funding in the context of prominent national debate about taxation and healthcare spending reveal the satisfaction with the NHS to have dwindled across all services and demographics in 2023. Public contentment has sharply declined, with only 24 per cent expressing satisfaction in 2023, a significant drop from 2020. Factors contributing to this dissatisfaction include prolonged waiting times for GP and hospital appointments, staffing shortages, and perceived inadequate government spending.

Pharmadoctor, a company which provides clinical service packages to pharmacists, has announced the launch of the UK's first private Covid vaccination service via its nationwide network of partner community pharmacies. For the first time, people who are eligible for the Covid-19 vaccine (those aged 12 years and over) will be able to get the shots from their local independent pharmacy by paying as little as £45 per jab, the company said. The delivery of the new service is expected to start by 1st April at the latest by "thousands of pharmacists" using the Pharmadoctor eTool. To encourage pharmacists to sign up early to provide the service, the company is offering its package at half-price until 31st March.

The latest findings from the National Cancer Patient Experience Survey 2022 by QualityWatch, a joint programme with the Nuffield Trust and the Health Foundation shed light on concerning disparities faced by ethnic minority communities in the UK healthcare system. Despite strides in cancer care, the survey highlights persistent challenges in easy and equitable access to timely diagnosis and quality communication, particularly for individuals from Mixed, Black, or Asian backgrounds. Key insights from the survey underscored that individuals from ethnic minority groups often require a higher number of interactions with healthcare professionals before receiving a cancer diagnosis. Notably, one in three people from Mixed, Black, or Asian ethnicities needed three or more visits to a GP practice, compared to the average of one in five across the population. These delays in diagnosis can have significant implications for treatment outcomes and overall patient experience. Moreover, the survey revealed concerning trends regarding the quality of communication following a cancer diagnosis among ethnic minority patients.